Patents by Inventor Andrew E. Denker

Andrew E. Denker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING PREGNANCY-ASSOCIATED ATYPICAL HEMOLYTIC UREMIC SYNDROME USING AN ANTI-C5 ANTIBODY
    Publication number: 20230043576
    Abstract: Provided are methods for clinical treatment of pregnancy-associated atypical haemolytic uraemic syndrome (p-aHUS), including postpartum aHUS, using an anti-C5 antibody, or antigen binding fragment thereof, such as ravulizumab (ULTOMIRIS®).
    Type: Application
    Filed: December 18, 2020
    Publication date: February 9, 2023
    Applicant: Alexion Pharmaceuticals, Inc.
    Inventor: Andrew E. Denker
  • Methods for treating hypophosphatasia (HPP) in adults and adolescents
    Patent number: 11224637
    Abstract: The disclosure features methods for treating hypophosphatasia (HPP) in a patient (e.g., an adult having HPP, such as an adult having pediatric-onset HPP, or an adolescent having HPP) exhibiting decreased pyrophosphate (PPi) or pyridoxal 5?-phosphate (PLP) concentrations in, e.g., a plasma sample, physical impairments, or decreased walking ability by administering a soluble alkaline phosphatase (sALP) to the patient.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: January 18, 2022
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Scott Edward Moseley, Andrew E. Denker, Wei-Jian Pan
  • METHODS FOR TREATING HYPOPHOSPHATASIA (HPP) IN ADULTS AND ADOLESCENTS
    Publication number: 20200101141
    Abstract: The disclosure features methods for treating hypophosphatasia (HPP) in a patient (e.g., an adult having HPP, such as an adult having pediatric-onset HPP, or an adolescent having HPP) exhibiting decreased pyrophosphate (PPi) or pyridoxal 5?-phosphate (PLP) concentrations in, e.g., a plasma sample, physical impairments, or decreased walking ability by administering a soluble alkaline phosphatase (sALP) to the patient.
    Type: Application
    Filed: March 29, 2018
    Publication date: April 2, 2020
    Inventors: Scott Edward MOSELEY, Andrew E. DENKER, Wei-Jian PAN
  • Liquid bisphosphonate formulations for bone disorders
    Publication number: 20030139378
    Abstract: The present invention relates to high dose oral liquid formulations of bisphosphonate and their methods of use to treat/prevent diseases related to bone remodeling or bone disorders, such as for example, Paget's disease, osteoporosis, metastatic bone disease, hypercalcemia of malignancy, periprosthetic osteolysis, periodontal disease, arthritic conditions, and the like, while minimizing the potential for esophageal irritation and other adverse gastrointestinal effects. These methods comprise orally administering to a mammal in need thereof a pharmaceutically effective amount of the liquid pharmaceutical composition of at least one bisphosphonate, or a pharmaceutically acceptable salt thereof, as a unit dosage according to a continuous schedule having a once-weekly, twice-weekly, biweekly, twice-monthly, or monthly dosing interval. The present invention also relates to liquid pharmaceutical compositions of the bisphosphonate for carrying out these methods.
    Type: Application
    Filed: November 26, 2002
    Publication date: July 24, 2003
    Inventors: Anastasia G. Daifotis, Albert T. Leung, Andrew E. Denker, Paul A. Bergquist